Her initial chest X-ray showed a multifocal abscessing pneumonia (Fig. 1A). CT was immediately performed which confirmed multifocal abscessus in lungs (Fig. 1B). Admission labs revealed hemoglobin 12.5 gm/dL, white count 8.8 × 10^9/L, neutrophil 5.99 × 10^9/L, platelets count 197 × 10^9/L. Her serum sodium levels were 138 mEq/L, and the blood urea nitrogen (BUN) and creatinine values were 20 mg/dL and 0.9 mg/dL respectively. C reactive protein (CRP) was 252 ng/ml, while procalcitonin was 78.7 µg/L. Arterial blood gas showed a pH of 7.30 and PaO2 of 60 mmHg, PCO2 46 mmHg, SaO2 90%.

Initially, the patient was started empirically with broad-spectrum antibiotics: Vancomycin 1 g/12 h, Amikacin 1 g/12 g and Orvagyl 550 mg/8 h. Blood culture, throat culture, blood fungal culture, acid-fast bacillus blood culture, and urine culture were all negative. Despite antibiotics therapy, patient was febrile up to 38 °C, and in the absence of adequate laboratory as well as radiologically answer, therapy was changed into Meropenem 1 g/12 h and Orvagyl 550 mg/8 h. On third day, patient was afebrile and feeling better. Her CRP was 9.7 mg/ml, white count 11.2 × 10^9/L, platelets 210 × 10^9/L. During the following days, the patient’s condition, and laboratory parameters improved in parallel with the neutrophil count. She received above mentioned therapy for fourteen days after she was discharged in good condition and radiological finding. She was released from the hospital with recommended Propylthiouracil 50 mg twice daily. She was regularly checked up by endocrinologist and pneumologist with no relapse of disease.

Antithyroid drugs, especially thioamides—including propylthiouracil, methimazole and carbimazole—have adverse hematological effects, ranging from mild leukopenia to agranulocytosis and aplastic anemia. Agranulocytosis, defined as a marked decrease in the number of granulocytes, frequently <500/µL, is a rare complication. Fever and sore throat are common symptoms of antithyroid drug induced agranulocytosis. Patients with an absolute neutrophil count <100/µL tend to have a greater risk of infectious and fatal complications than do patients with a neutrophil count >100/µL. The mortality rate is greater in patients aged >65 years than in those aged <65 years.

The lungs are the most common organ to be infected in febrile neutropenic patients. The chest radiograph is the standard initial investigation to look for pulmonary changes, but its sensitivity has been shown to be very low. High resolution computed tomography (HRCT) chest can detect the abnormality with a high degree of accuracy, as well as differentiate between different types of infections.

It is extremely useful in early detection or exclusion of a focus of infection and characterization of the focus. Exact etiological diagnosis is not possible in most of the cases, but identification of broad category of infective causes itself is very important for the appropriate therapy. Previous studies have proven that the most common cause of febrile condition is Pseudomonas aeruginosa. Our case was different from previous described in literature, in its beginning, but similar in good prognosis after granulocyte colony-stimulating factor and empirical antibiotic therapy. However, the recovery time in our cases was slightly longer than in previous cases (14 vs. 6.8 days). Nowadays, more people are undergoing surgical treatment as a permanent solution.

In conclusion, ATD-induced agranulocytosis is rare, but the severity of this possibly life-threatening condition means its management is essential to a good prognosis. Our case suggests that patients with antithyroid drug-induced agranulocytosis who present with severe infections should be treated empirically with broad-spectrum antibiotics with antipseudomonal activity.

Alternative way in patients with hyperthyroidisms is surgery or radioactive iodine which seem to be effective options to restore an euthyroid state. In fact, radioactive iodine was demonstrated as a successful option, with 88.8% of patients experiencing euthyroidism after treatment.

References


Biljana Lazovic, a,b,c* Vuk Andrejevic, a Aleksandar Ivanovic, a Vladimir Zugic a,c

a University Clinical Center “Zemun”, Belgrade, Serbia
b Clinic for Lung Diseases, Clinical Center of SERBIA, Belgrade, Serbia
c School of Medicine, University of Belgrade, Serbia

* Corresponding author.
E-mail address: lazovic.biljana@gmail.com (B. Lazovic).

1579-2129/ © 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

PD-L1 Expression in a Non-Small Cell Lung Cancer Specimen Obtained by EBUS-TBNA

Expresión de PD-L1 en muestras de cáncer pulmonar no microcitico obtenidas por EBUS-TBNA

To the Editor,

Lung cancer is the leading cause of cancer death worldwide among both men and women, accounting for 1.6 million deaths annually. In Chile, it is the second leading cause of death due to cancer.1 Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers; unfortunately, up to 80% of cases are diagnosed in advanced stages, requiring systemic therapy. In recent decades, significant advances have been made in the treatment of these patients, with the development of therapies aimed at specific mutations of the tumor cells (targeted therapies) and more recently with immunotherapy.

Among the most widely used immunotherapies are monoclonal antibodies against PD-1 or PD-L1. Their action is based on the ability of some tumors to evade the immune system through the expression of PD-L1, a ligand for a protein called PD-1 (programmed cell death protein 1). When PD-1 and PD-L1 bind, T cell activation is inhibited, thus blocking the normal immune response to tumor

* Please cite this article as: Fernandez-Bussy S, Pires Y, Labarga G, Vial MR. Expresión de PD-L1 en muestras de cáncer pulmonar no microcitico obtenidas por EBUS-TBNA. Arch Bronconeumol. 2018;54:290–292.
cells. Some of these therapies are already approved for the treatment of lung cancer, and show longer survival rates than those obtained with conventional chemotherapy.\(^5\)

One of the most important challenges in the use of PD-L1 inhibitors is correct patient selection. One of the most commonly used markers is PD-L1 expression in tumor cells, which is evaluated using immunohistochemical techniques. Pembrolizumab is an anti-PD-L1 monoclonal antibody approved for the treatment of NSCLC. First-line therapy with pembrolizumab requires that at least 50% of the tumor cells express PD-L1, and for second-line therapy, at least 1%.\(^5\)

The studies that led to the approval of anti-PD-L1 therapies were all conducted using large tissue samples from either excisional biopsies or core biopsies.\(^5\)\(^-\)\(^7\) Such samples are not always available in NSCLC patients, since diagnosis is often made with smaller samples obtained with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). This is a minimally invasive technique that has been recommended by many scientific societies as the diagnostic procedure of choice in central airway lesions or those which require mediastinal staging.\(^8\)\(^-\)\(^9\) The usefulness of this type of biopsy for measuring PD-L1 expression is unclear, and may differ in terms of diagnostic accuracy, fundamentally because of the number of tumor cells in these samples. We report here on the feasibility of determining PD-L1 expression in NSCLC samples obtained by EBUS-TBNA.

We conducted a retrospective review of all NSCLC cases in whom PD-L1 studies were requested. The cases were identified from the pathology laboratory database, and we included all patients seen between July 1, 2015, when this technique was first available in our hospital, and June 1, 2017. The study was approved by the ethics committee of our institution. Histopathological diagnosis and PD-L1 expression analysis were performed by an expert pathologist specializing in lung diseases. Samples were considered adequate for PD-L1 staining if they contained more than 100 evaluable cancer cells. The samples were fixed in 4% formaldehyde, buffered, and embedded in paraffin; 4 μm tissue slices were cut and stained with hematoxylin–eosin, and incubated with anti-PD-L1 monoclonal antibody (E1L3N® XP® Rabbit mAb) in the Ventana Benchmark ULTRA automated system (Roche), according to the recommendations of the manufacturer. PD-L1 expression was evaluated with a manual count of the percentage of cancer cells with membrane staining, whether partial or complete, and irrespective of intensity (Fig. 1A–D).

All samples from the total 23 requests for PD-L1 determination were adequate for the procedure. Of these 23 cases, 18 were adenocarcinomas, 3 squamous cell carcinoma, 1 adenosquamous, and 1 unspecified non-small cell carcinoma.

Mean age was 70 years (range 41–88), and most patients (12/23, 52%) were women. The samples were lymph node aspirates in 20/23 patients (87%), and the others were from lesions adjacent to the central airway.

Among the 23 cases analyzed, we found 3 (13.04%) samples with PD-L1 staining in >50% of the cancer cells, 6 (26.08%) with staining in 1%–50%, and 14 (60.86%) with staining in <1%. Of the 14 cases with staining in <1%, 11 showed no staining. The results of anti-PD-L1 immunohistochemical staining in cancer cells are shown in Table 1.

This study suggests that, similarly to their use in the determination of the most common mutations,\(^7\)\(^,\)\(^11\) in a high percentage of cases, EBUS-TBNA samples are adequate for evaluating PD-L1 expression in cancer cells. Only 13% of samples were positive, defined as staining of more than 50% of the cancer cells (95% CI: 0.028–0.336), while the vast majority of cases were negative for PD-L1 expression. When 1% was used as a cut-off point, positivity rose to 26% (95% CI: 0.10–0.48).

Very few studies have evaluated PD-L1 expression in samples obtained by EBUS-TBNA.\(^11\)\(^,\)\(^12\) Larger biopsy samples yield PD-L1 positivity of around 50% with a cohort cut-off point >50%.\(^7\)\(^,\)\(^13\) Although these figures appear to be higher than those observed in our group, this may be a chance occurrence, due to the limited

![Fig. 1. Microscopic images of the tumor samples obtained by EBUS-TBNA and of the respective immunohistochemical stains with anti-PD-L1 E1L3N antibody. (A) Adenocarcinoma (hematoxylin–eosin, 40×). (B) Membrane staining of >50% of cancer cells (PD-L1 E1L3N XP Rabbit mAb, 40×). (C) Adenocarcinoma (hematoxylin–eosin, 40×). (D) Membrane staining of >1% of cancer cells (PD-L1 E1L3N XP Rabbit mAb, 40×).](image-url)
Table 1
Characteristics of EBUS-TBNA Samples Tested for PD-L1.

<table>
<thead>
<tr>
<th>Source of sample</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymph node</td>
<td>20</td>
</tr>
<tr>
<td>Lung</td>
<td>3</td>
</tr>
</tbody>
</table>

number of cases in our series (reflected by the wide confidence interval). If the number of PD-L1-positive samples really is lower than reported in the literature, this may be associated with ethnic differences among our population, and also with differences in the techniques used, for example, due to tumor heterogeneity.

This is the first study in South America to evaluate the feasibility of measuring PD-L1 in EBUS-TBNA samples. Unfortunately, it has the limitations associated with a small number of patients, and a population recruited from the same hospital. It should be noted that while it is possible to measure PD-L1 in samples obtained by EBUS, we cannot determine if the positivity observed in samples obtained by needle aspiration is representative of positivity in the primary tumor, and, more importantly, if these samples are useful for predicting response to therapy. These questions must be answered in further studies.

References


Sebastián Fernandez-Bussy, a, Yumai Pires, b Gonzalo Labarca, c,d Macarena R. Vial b

a Unidad de Neumología Intervencionista, Clínica Alemana de Santiago-Universidad del Desarrollo, Santiago, Chile
b Departamento de Anatomía Patológica, Clínica Alemana de Santiago-Universidad del Desarrollo, Santiago, Chile
c Departamento de Medicina, Universidad San Sebastián, Concepción, Chile
d Departamento de Medicina Interna, Complejo Asistencial Dr. Víctor Ríos Ruiz, Los Ángeles, Chile

* Corresponding author.
E-mail address: sfernandezbussy@alemana.cl (S. Fernandez-Bussy).

1579–2129/ © 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.